Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ASPH | Q12797 | 1/20 | 0.50 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.46 |
| ▸ | KDM5A | P29375 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31043221 | 0.82 | ATR (0.49) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL30411449 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL23971140 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL31713567 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL29486104 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL392396 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL83616 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL9704180 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| Hydrochloric Acid SCHEMBL9355662 | 0.79 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAKDM4EASPHKDM8 | |
| SCHEMBL27488847 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2LMNAKDM4EASPHKDM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590343-B2 | Corrosion inhibitor composition for magnesium or magnesium alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2020-03-17 | — | — | US | claimed |
| EP-3284847-B1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | HELMHOLTZ ZENTRUM GEESTHACHT (DE) | 2019-01-02 | — | — | EP | claimed |
| EP-3284847-A1 | CORROSION INHIBITOR COMPOSITION FOR MAGNESIUM OR MAGNESIUM ALLOYS | Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH (DE) | 2018-02-21 | — | — | EP | claimed |
| US-20180044590-A1 | Corrosion Inhibitor Composition for Magnesium or Magnesium Alloys | Helmholtz-Zentrum Geesthacht Zentrum für Material-und Küstenforschung GmbH (DE) | 2018-02-15 | — | — | US | claimed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-6946472-B2 | Polycyclic compounds exhibiting anti-tumor activities | HOFFMAN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| CN-1610681-A | Polycyclic compounds having anti-tumor activity | HOFFMANN LA ROCHE (CH) | 2005-04-27 | — | — | CN | disclosed |
| EP-1436293-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6680326-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093265-A1 | DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | SMN1; SMN2 4258/4885LMNA 2339/4885KDM4E 1718/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | SMN1; SMN2 4524/4885LMNA 3187/4885KDM4E 1010/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
| US-20220324854-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885LMNA 1656/4885KDM4E 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.